Business
Globus Medical completes acquisition of Nevro Corp.
AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. “We are excited to begin the journey of accelerating market penetration of Nevro’s differentiated high-frequency technology and bringing a much-needed treatme
About this update from Globus Medical, Inc.
[{"type":"image","alt":"Globus Medical","displaySize":"","headline":null,"caption":"Globus Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":236,"url":"https://media.zenfs.com/en/globenewswire.com/00da90d72bee150b4be4104613ae2ce4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HbC9jzNGkCK8ASuuAaxfXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/00da90d72bee150b4be4104613ae2ce4","width":300,"height":236}},"lazy":false},{"type":"text","content":"AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain.","length":346,"tagName":"p"},{"type":"text","content":"“We are excited to begin the journey of accelerating market penetration of Nevro’s differentiated high-frequency technology and bringing a much-needed treatment option to patients suffering from chronic pain,” said Dan Scavilla, president and CEO of Globus Medical.","length":275,"tagName":"p"},{"type":"text","content":"The acquisition of Nevro further expands Globus Medical's presence in the musculoskeletal market, unlocking a $2.5 billion market opportunity. This strategic move positions Globus to further add to its product portfolio with the potential to alter the standard of care in the neuromodulation space and beyond.","length":313,"tagName":"p"},{"type":"text","content":"Globus Medical plans to discuss the closing of the acquisition and the anticipated benefits of the expanded product offering during its first quarter earnings conference in May.","length":182,"tagName":"p"},{"type":"text","content":"Nevro Corp. common stock ceased trading on the New York Stock Exchange prior to the open of the market on April 3, 2025. Further information about the transaction can be found in the Form 8-Ks filed with the SEC today by Nevro Corp. and Globus Medical, respectively.","length":286,"tagName":"p"},{"type":"text","content":"Financial and Legal AdvisorsMorgan Stanley & Co. LLC served as financial advisor to Globus Medical, and Wyrick Robbins Yates & Ponton LLP se...